Clinical data | |
---|---|
Trade names | Elfabrio |
Other names | PRX-102, pegunigalsidase alfa-iwxj |
License data |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
DrugBank |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C2060H3130N552O601S27 |
Molar mass | 46110.58 g·mol−1 |
Pegunigalsidase alfa, sold under the brand name Elfabrio, is an enzyme replacement therapy for the treatment of Fabry disease.[2][4] It is a recombinant human α-galactosidase-A.[4] It is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme.[2]
The most common side effects are infusion-related reactions, hypersensitivity and asthenia.[4]
Pegunigalsidase alfa was approved for medical use in both the European Union and the United States in May 2023.[4][3]
Elfabrio EPAR
was invoked but never defined (see the help page).